HELIX BIOPHARMA CORP (HBP.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:HBP - CA4229102088 - Common Stock
HBP.CA Key Statistics, Chart & Performance
The current stock price of HBP.CA is 2.37 CAD. In the past month the price increased by 2.6%. In the past year, price increased by 216%.
HBP.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 522.71M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 416.39M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 76.74M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.86 | 48.06M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 31.97M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.73M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.42M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.96M | ||
| MPH.CA | MEDICURE INC | N/A | 11.90M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.03M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 5.92M |
Related stock screener links
About HBP.CA
Company Profile
Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company is headquartered in Toronto, Ontario. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The firm is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.
Company Info
HELIX BIOPHARMA CORP
Bay Adelaide Centre - North Tower 40, Temperance Street, Suite 2700 Toronto
TORONTO ONTARIO L4B 3J9 CA
CEO: Heman Chao
Employees: 7
Phone: 16046842181
HELIX BIOPHARMA CORP / HBP.CA FAQ
What does HELIX BIOPHARMA CORP do?
Helix BioPharma Corp. is an immuno-oncology company, which engages in the development of products for the treatment and prevention of cancer. The company is headquartered in Toronto, Ontario. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The firm is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.
What is the current price of HBP stock?
The current stock price of HBP.CA is 2.37 CAD. The price increased by 3.49% in the last trading session.
Does HBP stock pay dividends?
HBP.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of HBP stock?
HBP.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of HELIX BIOPHARMA CORP (HBP.CA)?
HELIX BIOPHARMA CORP (HBP.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
Would investing in HELIX BIOPHARMA CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HBP.CA.
When does HELIX BIOPHARMA CORP (HBP.CA) report earnings?
HELIX BIOPHARMA CORP (HBP.CA) will report earnings on 2026-03-12.
HBP.CA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to HBP.CA. When comparing the yearly performance of all stocks, HBP.CA is one of the better performing stocks in the market, outperforming 88.73% of all stocks.
HBP.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HBP.CA. The financial health of HBP.CA is average, but there are quite some concerns on its profitability.
HBP.CA Financial Highlights
Over the last trailing twelve months HBP.CA reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 56.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.58% | ||
| ROE | -30.36% | ||
| Debt/Equity | 0.02 |